Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Peking University Cancer Hospital, Fujian Provincial Cancer Hospital, Shandong Tumor Hospital, Zhejiang Cancer Hospital, Anyang Tumor Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, First Affiliated Hospital of Zhengzhou University, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Henan University of Science and Technology, Fudan University, Zhongshan Hospital, Sichuan Cancer Hospital, Sir Run Run Shaw Hospital, Zhejiang University, Henan Cancer Hospital, First Hospital of Jilin University, Jiangsu Cancer Hospital, Sichuan Baili Pharmaceutical Co., Ltd. (China)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162490153